Anatomy explorers have charted a new path myeloid cells use to access the brain. On 3 June in Neuron, scientists led by Lindsay Hohsfield and Kim Green, both at the University of California, Irvine, ...

Their analysis of three large population studies found that age-adjusted prevalence has dropped by a whopping two-thirds over the last 40 years. In other words, every successive birth cohort has a ...

Despite growing recognition of the importance of the peripheral immune system in neurodegenerative disease, little is known about how these blood cells change in Alzheimer’s and Parkinson’s diseases.

Of the 20,000+ human genes, none has greater influence on late-onset Alzheimer’s disease than APOE. But why do certain variants of this lipid transporter protect the brain, while others endanger it? A ...

The advisory committee voted 11 to 0 on both questions in favor of the approval of donanemab. The committee recognized, correctly I think, that the data supported a modestly favorable benefit to risk ...

Research over the last decade has shown that aggregated Aβ seeds can be transferred between people during rare medical procedures, sparking amyloidosis in the recipient. Could this result in ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

Fox added that peer-reviewed studies are needed to fully understand the sensitivity and specificity of the approach. One preprint, and findings presented at CTAD conferences in 2020 and 2021, suggest ...

The latest effort to rewrite the diagnostic criteria for Alzheimer’s disease has stirred more than a little controversy. While the proposed revisions have garnered praise from researchers for more ...

People with ApoE3 Christchurch variant stave off even autosomal-dominant Alzheimer’s disease by keeping neurofibrillary tangles at bay. Could people born without this protective mutation reap its ...

Current diagnostic options for PD include DaTscan SPECT to assess dopamine transporter activity, the Syn-One test to detect α-synuclein aggregates in a skin biopsy, or the SYNTap α-synuclein seed ...

However, diagnostic tests do not need FDA approval to be marketed to the public. They can clear a lower bar by becoming CLIA-approved, meaning the assay has good test-retest reproducibility. Quest's ...